ArticleChemistry & biodiversity2026
In Silico and In Vitro Antiurolithic Effect of Extracts, Fractions, and Isolated Compounds From Eugenia mattosii.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Urolithiasis, a condition characterized by the formation of calcium oxalate stones in the urinary tract, remains a significant clinical challenge due to the limited availability of effective preventive therapies. This study investigated the antiurolithic potential of different preparations from Eugenia mattosii, a plant rich in phenolic constituents. Calcium oxalate (CaOx) precipitation was induced in rat urine samples. Potassium citrate (10 mg/mL) was used as the positive control, while the crude methanolic extract (CME), chloroform fraction (CLF), ethyl acetate fraction (EAF), pinostrobin (PIN), and cryptostrobin (CRY) were tested at concentrations ranging from 0.01 to 1 mg/mL. CME and EAF increased CaOx crystal formation, whereas CLF, PIN, and CRY significantly reduced crystal formation at 0.01 mg/mL. In silico ADMET analysis supported favorable pharmacokinetic and safety profiles for PIN and CRY. Molecular docking revealed strong interactions with MMP-9, suggesting a potential inhibitory effect that may reduce tissue injury and crystal nucleation. Overall, CLF and its flavonoids demonstrate promising antiurolithic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.